Methods of preventing tissue damage associated with decreased blood flow by administration of AICA riboside compounds

摘要

Methods of preventing tissue damage associated with decreased blood flow in a human by administering AICA riboside or a prodrug thereof in an amount which provides a blood plasma concentration of between 1 mu g/ml and 20 mu g/ml of AICA riboside for a time sufficient to reduce the risk of said tissue damage in said human. Methods of preventing an adverse clinical outcome, such as an adverse cardiovascular and/or cerebrovascular event, in a patient at risk for such outcome by administering AICA riboside or a prodrug thereof in an amount which provides a blood plasma concentration of between 1 mu g/ml and 20 mu g/ml of AICA riboside for a time sufficient to reduce the risk for said patient.